DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines.

ABSTRACT: Vaccination remains the most effective and essential prophylactic tool against infectious diseases. Enormous efforts have been made to develop effective vaccines against malaria but successes remain so far limited. Novel adjuvants may offer a significant advantage in the development of malaria vaccines, in particular if combined with inherently immunogenic platforms, such as virus-like particles (VLP). Dioleoyl phosphatidylserine (DOPS), which is expressed on the outer surface of apoptotic cells, represents a novel adjuvant candidate that may confer significant advantage over existing adjuvants, such as alum. In the current study we assessed the potential of DOPS to serve as an adjuvant in the development of a vaccine against malaria either alone or combined with VLP using Plasmodium fa

SUBMITTER: Cabral-Miranda G 

PROVIDER: S-EPMC6313579 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature